| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | -0.029 | 0.5 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.5 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.029 | 0.5 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |